Fig. 1From: Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignanciesResponse to MEDI0680 therapy. a Tumor size change from baseline in the as-treated population. b The timing and duration of response and onset of progressive disease or new lesions in the responding population. Blue bars indicate treatment initiation to censoring date or progression date. One patient with kidney cancer and PR had an ongoing response but did not have a disease assessment at the time of the last doseBack to article page